ReportWire

Tag: Cell Biology

  • Sylvester Researcher Earns Prestigious Columbia University Award

    Sylvester Researcher Earns Prestigious Columbia University Award

    [ad_1]

    Newswise — MIAMI, FLORIDA (Sept. 20, 2023) – A researcher with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has been selected to receive a prestigious honor from Columbia University.

    Glen N. Barber, PhD, Sylvester’s internationally known cell biologist who chairs UM’s Department of Cell Biology, will be awarded the 2023 Louisa Gross Horwitz Prize from Columbia for outstanding contributions to basic research in biology and biochemistry.

    Barber is the first UM faculty member to receive this award, and more than 50% of previous honorees have gone on to win the Nobel Prize. The award, which carries a $10,000 prize was presented to Barber and fellow recipient, James Chen, at a recognition dinner in New York City.

    Barber is being honored for his transformational research discovery known as STING (stimulator of interferon genes), a pivotal pathway controlling immune responses to infections and inflammation that also plays a vitally important role in triggering anti-tumor T-cell activity.   

    Since making the discovery in 2008, Barber and his team have conducted extensive research into STING signaling and made significant discoveries that have spawned efforts to design novel drugs that target this pathway for new treatments of various diseases such as inflammatory bowel disease, systemic lupus and, more recently, leukemia and other cancers.

    “This award is a tremendous honor for which I am both humbled and grateful,” Barber said. “I will be accepting it on behalf of many colleagues, past and present, whose contributions have been invaluable to our collective success.”

    The Louisa Gross Horwitz prize was established at the bequest of the late S. Gross Horwitz and is named to honor his mother, the daughter of academic trauma surgeon Samuel D. Gross. The prize was first awarded in 1967. 

    Read more about this award on the InventUm Blog.  

    # # #

    [ad_2]

    Sylvester Comprehensive Cancer Center

    Source link

  • Cancer drug combo slows tumor growth

    Cancer drug combo slows tumor growth

    [ad_1]

    Newswise — An international team of researchers has demonstrated that a combination of inhibitors may suppress tumor growth and prevent relapse in patients with certain cancers, including head and neck squamous cell carcinoma and lung adenocarcinoma. Their findings support the future development of innovative therapeutic approaches targeting these cancers.

    The team’s work is published in the journal Oncogene on August 17, 2023.

    Scientists know that in humans and other mammals, the Hippo signaling pathway plays a key role in the rapid increase of cells that occurs with cancers in the body. Yes-associated protein 1, or YAP, is a protein that is critical in regulating the progression of tumor growth, and it plays an important role in the beginning and spread of a variety of cancers. When the Hippo pathway is dysregulated, it triggers the activation of YAP and this contributes to head and neck squamous cell carcinoma. Both the Hippo pathway and YAP have attracted attention as signaling pathways that regulate cancer cell characteristics.

    Epidermal growth factor receptor, or EGFR, is a protein on cells that contributes to their growth. When a mutation occurs in the gene for EGFR, it can grow too much, leading to cancer. EGFR is frequently amplified and highly overexpressed in head and neck squamous cell carcinoma, and mutated and activated in lung adenocarcinoma. So the EGFR inhibitor, a drug that blocks the cancer’s growth, is used as a targeted therapy in fighting these cancers. 

    In earlier work, the research team clarified the mechanism by which EGFR activates YAP through the Hippo pathway. However, EGFR-targeted monotherapy has shown a low response rate. Based on this evidence, researchers believe that EGFR inhibitors may temporarily inactivate YAP, but when YAP is re-activated, it increases resistance to the EGFR inhibitors used to fight the cancer. Scientists do not yet fully understand how the YAP is re-activated. 

    The team focused their current study on AXL, a receptor-type tyrosine kinase. They set out to clarify the mechanism that causes the cancer cells’ resistance to EGFR inhibitors, specifically focusing on the novel regulatory mechanism of YAP by AXL. Receptor-type tyrosine kinases like AXL play an important role in cell processes. When it is working properly, AXL is mainly expressed in immune cells, and does the work of removing dead cells and controlling the duration of immune responses. But when AXL becomes dysregulated, they can contribute to cancers, including lung adenocarcinoma, acute leukemia, and head and neck squamous cell carcinoma.

    The team used comprehensive transcriptional analysis and in vitro experiments in their study. With this research, the team clarified that AXL stimulates YAP through a novel mechanism when AXL combines with EGFR. This combination activates YAP via the EGFR-LATS1/2 axis. LATS1/2, or large tumor suppressor kinases, are important members of the Hippo pathway. The team determined that the combination of AXL and EGFR inhibitors working together inactivates YAP and suppresses the viability of head and neck squamous cell carcinoma and lung adenocarcinoma cells.

    “The combination therapy targeting both EGFR and AXL or YAP simultaneously may effectively suppress tumor growth and prevent resistance and relapse in patients with EGFR-altered cancers, including head and neck squamous cell carcinoma and lung adenocarcinoma,” said Toshinori Ando, assistant professor at the Center of Clinical Oral ExaminationHiroshima University Hospital

    Looking ahead, the team plans to try to generate effective drugs that can target EGFR, AXL, and YAP. “We think that intrinsic YAP activation or acquired re-activation after EGFR-targeted therapy in head and neck squamous cell carcinoma and lung adenocarcinoma has not been clarified yet. We will continue the research,” said J. Silvio Gutkind, distinguished professor, Department of Pharmacology, University of California, San Diego. 

    [ad_2]

    Hiroshima University

    Source link

  • 3D Stress Patterns in Capillaries Are Caused by Red Blood Cell Squeezing

    3D Stress Patterns in Capillaries Are Caused by Red Blood Cell Squeezing

    [ad_1]

    BYLINE: Mario Boone

    Newswise — Rockville, Md. (September 15, 2023)—New and unique shear stress patterns can occur in angiogenic capillary (new blood vessel growth) networks, according to a new study in the journal Function. There was also enhancement of low shear stress regions by red blood cells. Shear stress is the frictional force of the blood on the vessel wall. Researchers from the New Jersey Institute of Technology and the University of Florida found this is due to red blood cells getting squeezed and deformed in these hair-sized blood vessels.   

    The growth and adaptation of new blood vessels in the body is key to many physiological processes in health and disease. This is true from embryonic development and natural changes during the aging process to diabetes, heart disease and tumor growth in cancer.

    High-resolution computer simulations allowed researchers to demonstrate multiple types of 3D shear stress spatial variations which derive from distinct blood vessel surface shapes and structures. The research team was able to identify the existence of shear stress hot and cold spots caused by red blood cells interacting with these unique surface shapes. The researchers identified shear stress spatial patterns, which vary over time and help explain how fluctuations follow timescales of red blood cell “footprints.” 

    “Altogether, this study provides a conceptual framework for understanding how shear stress might regulate the formation of new blood vessels in a living organism,” said Peter Balogh, corresponding author of the study. 

    These findings inspire new research directions with a high potential to improve human health, including helping to predict tumor growth patterns and guiding new treatments. This allows for early detection of problems during embryonic development or developing new ways to improve blood flow in heart disease.

    Read the full article, “Angiogenic microvascular wall shear stress patterns revealed through three-dimensional red blood cell resolved modeling,” published ahead of print in Function. Contact APS Media Relations or call 301.634.7314 to schedule an interview with a member of the research team.

    [ad_2]

    American Physiological Society (APS)

    Source link

  • Third Elaine Redding Brinster Prize Awarded for Development of Sickle Cell Disease Therapy

    Third Elaine Redding Brinster Prize Awarded for Development of Sickle Cell Disease Therapy

    [ad_1]

    Newswise — PHILADELPHIA—For his work discovering the basis for hemoglobin gene switching and applying those insights to develop a therapy for sickle cell disease and other blood diseases, the Institute for Regenerative Medicine at the University of Pennsylvania awarded Stuart Orkin, MD the third Elaine Redding Brinster Prize in Science or Medicine.

    Orkin’s research advanced the understanding of how the fetal hemoglobin gene— the main oxygen carrier protein in the human fetus—is silenced in adults. He also developed a therapy that re-activates the fetal gene for adult hemoglobin gene defects, which cause red blood cell diseases.

    “Dr. Orkin has beautifully illustrated how a career of basic science investigation into the mechanisms for gene regulation can be applied, in one’s own laboratory, to a method for combating devastating human diseases. Notably, his discovery of unexpected details in how the fetal hemoglobin gene is regulated suggested insights for a therapy, for which he availed of the latest gene editing technologies to develop a specific clinical application for sickle cell disease,” said Ken Zaret, PhD, director of Penn’s Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology in the Perelman School of Medicine. “We are thrilled that Dr. Orkin is the third awardee of the Elaine Redding Brinster Prize.”

    The prize, supported by an endowment from the children of Elaine Redding Brinster, is awarded annually to a researcher whose singular discovery has made a unique impact on biomedicine. Each winner receives $100,000, a commemorative medal, and an invitation to present a ceremonial lecture at the University of Pennsylvania.

    Orkin will accept the prize on March 13, 2024, as part of the day-long Ralph L. Brinster Symposium at Penn’s Philadelphia campus. The symposium will feature eminent speakers from across the biomedical sciences, including Titia de Lange, PhD, of Rockefeller University; Carla Shatz, PhD, of Stanford University; Alejandro Sànchez Alvarado, PhD, of the Stowers Institute for Medical Research; and Marianne Bronner, PhD, of the California Institute of Technology.

    “I am very honored, and humbled, by recognition with the Brinster Prize. I hope that work of my laboratory will inspire others to pursue a career of fundamental discovery for the benefit of patients,” said Orkin, the David G. Nathan Distinguished Professor of Pediatrics, Harvard Medical School, and investigator with Howard Hughes Medical Institute.

    Orkin has been honored with several prestigious awards, including the Canada Gairdner International Award, the Gruber Foundation Prize in Genetics, the King Faisal Prize in Medicine, the Kovaleno Medal of the National Academy of Sciences, and the Harrington Discovery Institute Prize for Innovation in Medicine. Orkin is also a member of the U.S. National Academy of Medicine and National Academy of Sciences.

    Previous recipients of the Elaine Redding Brinster Prize include molecular biologist C. David Allis, PhD, and neurogeneticist Huda Zoghbi, MD.

    The Penn Institute for Regenerative Medicine is dedicated to researching cells and tissues with an eye toward turning the knowledge gained into new diagnostic and therapeutic techniques and tools. A member of the International Society for Stem Cell Research’s (ISSCR) Circle of Stem Cell Institute and Center Directors, the institute features faculty from five schools across the University of Pennsylvania and includes representation from Children’s Hospital of Philadelphia and the Wistar Institute.

     

    ###

     

    Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

    The Perelman School of Medicine is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

    The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

    Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

    [ad_2]

    Perelman School of Medicine at the University of Pennsylvania

    Source link

  • Certain proteins in breast milk found to be essential for a baby’s healthy gut

    Certain proteins in breast milk found to be essential for a baby’s healthy gut

    [ad_1]

    Newswise — More than 320 million years of mammalian evolution has adapted breast milk to meet all the physiological needs of babies: it contains not only nutrients, but also hormones, antimicrobials, digestive enzymes, and growth factors. Furthermore, many of the proteins in breast milk, for example casein and milk fat globule membrane proteins, aren’t just sources of energy and molecular building blocks, but also directly stimulate immunity, at least under preclinical conditions.

    Likewise, the gut microbiome, composed of bacteria, archaea, and fungi, plays a vital role in the regulation of the immune system. This raises the possibility that the immune-boosting function of breast milk proteins might be two-pronged: not only by stimulating the immune system directly, but also indirectly, by regulating the abundance of gut microbes which in turn impact immunity. 

    Now, a study by Chinese researchers in Frontiers in Microbiology finds the first evidence for the latter, roundabout, immunity-regulating function of breast milk proteins. The authors showed that variation in the protein composition of breast milk between mothers explains much of the variation in the abundance of key beneficial microbes in the gut of their babies, suggesting a regulatory role of these proteins on the immune function of the gut microbiome in humans. 

    “Here we show that the concentration of certain proteins in human breast milk predicts the abundance of specific gut microorganisms in infants, which are known to be important necessary for health,” said joint senior author Dr Ignatius Man-Yau Szeto from the Yili Maternal and Infant Nutrition Institute in Beijing. “These findings suggest that maternal proteins play a role in the early immune and metabolic development of immunity of babies.”

    Szeto and colleagues studied the association between the protein composition of 23 Chinese mothers – measured by ultra-performance liquid chromatography-mass spectrometry – and the diversity and abundance of beneficial gut microbes in the stools of their infants, determined through rRNA sequencing and quantitative real-time PCR.

    Focus on nine proteins

    “We focused on nine milk proteins, including osteopontin, lactalbumin, and κ-casein, because these were recently found to benefit the early development of infants. Their function and mechanisms haven’t yet been fully discovered, so we wanted to examine their potential role in regulating the microbiome of infants,” said co-senior author Dr Ai Zhao from Tsinghua University.

    The concentration of proteins in breast milk was 1.6% at 42 days after delivery, and 1.2% at three months after delivery. The most abundant proteins were casein, α-lactalbumin, and lactoferrin. Except for immunoglobulin A (an antibody important for the immune function of mucous membranes), the concentration of all studied proteins decreased from 42 days to three months post-partum. The gut microbiome of the babies was mainly composed of the bacterial genera BifidobacteriumEscherichiaStreptococcus, and Enterobacter.

    Link to probiotics

    The researchers found the strongest associations between the concentrations of breast milk proteins and two beneficial bacteria that were relatively rare within the gut microbiome of the babies: Clostridium butyricum and Parabacteroides distasonis, both used as probiotics for humans and domestic animals.

    For example, variation in the concentration of κ-casein in mother’s milk explained much of the variation in abundance of C. butyricum in the gut of their babies, while variation in the concentration of osteopontin explained much of the variation in abundance of P. distasonis. The first of these bacteria is known to regulate gut homeostasis and combat inflammatory bowel disease. The second, to counter diabetes, colorectal cancer, and inflammatory bowel disease.

    “The results of this study suggest that specific proteins in breast milk can influence the abundance of certain gut microbes in infants, playing an important role in early immune and metabolic development,” concluded the authors.

    The authors cautioned that further studies are necessary.

    “Our findings are based on correlations, which are not enough to establish a direct causal effect. Future cohort studies and clinical trials, where breast milk or formula is fortified with functional proteins are needed to prove this,” said Szeto.

    ###                                                                                                

     

    For editors / news media:

     

    Please link to the open access original research article “Functional proteins in breast milk and their correlation with the development of the infant gut microbiota: A study of mother-infant pairs” in Frontiers in Microbiology in your reporting: https://www.frontiersin.org/articles/10.3389/fmicb.2023.1239501/full

     

    [ad_2]

    Frontiers

    Source link

  • Ochsner MD Anderson First in Louisiana to Use CAR T cell Therapy to Treat Cancer in Adults

    Ochsner MD Anderson First in Louisiana to Use CAR T cell Therapy to Treat Cancer in Adults

    [ad_1]

    Newswise — NEW ORLEANS, La. – Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans is proud to be the first institution in Louisiana to use CAR T cell therapy in adults, the revolutionary treatment for certain types of blood cancers.

    A New Orleans adult patient received CAR T cell therapy in June, with a complete response and no evidence of cancer in late July, putting them in full remission. The patient is being treated under the guidance of Clark Alsfeld, MD, hematologist/oncologist and cellular therapy specialist at Ochsner MD Anderson.

    CAR T cell therapy, also known as Chimeric Antigen Receptor T cell therapy, is an innovative, personalized form of immunotherapy treatment that harnesses the patient’s immune system to target and destroy cancer cells.

    How does CAR T cell therapy work?

    The patient’s own T cells, a type of white blood cell, are extracted from their blood. These T cells are then genetically modified in a laboratory to express chimeric antigen receptors (CARs) on their surface.

    These CARs are designed to recognize specific proteins, known as antigens, that are present on the surface of cancer cells. Once the T cells are modified and expanded in number, they are infused back into the patient’s bloodstream. The engineered CAR T cells then seek out and bind to the cancer cells, leading to their destruction.

    CAR T cell therapy is particularly effective against certain types of blood cancers, such as acute lymphoblastic leukemia (ALL), certain types of non-Hodgkin lymphoma and multiple myeloma. Patient eligibility depends on the type of cancer and prior treatment—some must have already gone through multiple unsuccessful standard treatments. However, recent studies have even shown a benefit for CAR T cell therapy in certain patients with non-Hodgkin lymphoma after one line of therapy. Given this success, clinical trials at Ochsner MD Anderson and MD Anderson Cancer Center in Houston are evaluating CAR T cell therapy as first-line treatment in non-Hodgkin lymphoma.

    The success of CAR T cell therapy is very promising, with significant remission rates observed in patients who have not responded to standard cancer treatments, as evidenced by Ochsner

    MD Anderson’s first patient. CAR T cell therapy represents a momentous advancement in cancer treatment and has the potential to revolutionize the way certain types of cancers are managed. Ongoing research and development are focused on expanding its use to other cancer types, including solid tumors, and improving its safety and efficacy.

    “While a patient’s cancer journey can be challenging, CAR T cell therapy empowers the immune system to rise as a force against cancer cells—paving the way for advancements in ending cancer,” said Dr. Alsfeld. “At Ochsner MD Anderson, we are continuously striving to treat our patients with some of the latest and most effective treatment options to give them more good days with their families. We are thrilled that our first CAR T cell patient’s treatment was successful and look forward to helping more people.”

    Since Ochsner MD Anderson’s first CAR T cell patient’s therapy in June, its Bone Marrow Transplant and Cellular Therapy team has begun the CAR T cell treatment process on one additional patient and is currently evaluating three others, with more patients to receive the treatment this fall.

    For more than 80 years, Ochsner has been dedicated to cancer research and new cancer therapy development, bringing innovations to treatment with more clinical trials than anywhere else in Louisiana. It is accredited by the Commission on Cancer of the American College of Surgeons, the American Society of Clinical Oncology, the American College of Radiology, the Foundation for the Accreditation of Cellular Therapy (Bone Marrow Transplant) and the National Accreditation Program for Breast Centers.

    In June 2023, Ochsner Health announced a partnership with The University of Texas MD Anderson Cancer Center to create Ochsner MD Anderson Cancer Center in southeastern Louisiana, providing the region’s patients with access to cancer treatments among the most advanced in the nation. Through this collaboration, Ochsner is the first and only provider in Louisiana with a fully integrated cancer program based on MD Anderson’s standards and treatment plans.

    Cancer care at Ochsner is recognized by U.S. News & World Report, ranking as high performing in leukemia, lymphoma and myeloma treatment and colon, lung and prostate cancer surgeries. Ochsner’s ear, nose and throat specialty is also ranked by U.S. News & World Report as a top 50 program in the country, which includes head and neck surgical oncology. The Ochsner Cancer Institute treats more than 40,000 patients each year and has cared for patients from all 50 states and 28 countries. Each patient’s care team can include as many as 20 multidisciplinary cancer specialists working together to provide high-quality treatment. In 2022, more than 300,000 preventive cancer screenings were performed at Ochsner facilities across its system.

    To learn more about Ochsner MD Anderson Cancer Center and the treatment options available to patients, please visit ochsner.org/cancerservices.

     ###

    About Ochsner Health

    Ochsner Health is an integrated healthcare system with a mission to Serve, Heal, Lead, Educate and Innovate. Celebrating more than 80 years of service, it leads nationally in cancer care, cardiology, neurosciences, liver and kidney transplants and pediatrics, among other areas. Ochsner is consistently named both the top hospital and top children’s hospital in Louisiana by U.S. News & World Report. The not-for-profit organization is inspiring healthier lives and stronger communities through its Healthy State initiative, a bold and collaborative plan to realize a healthier Louisiana. Its focus is on preventing diseases and providing patient-centered care that is accessible, affordable, convenient and effective. Ochsner Health pioneers new treatments, deploys emerging technologies and performs groundbreaking research, including 4,000 patients enrolled in 685 clinical studies in 2022. It has more than 37,000 employees and over 4,700 employed and affiliated physicians in over 90 medical specialties and subspecialties. It operates 46 hospitals and more than 370 health and urgent care centers across Louisiana, Mississippi, Alabama and the Gulf South; and its cutting-edge Connected Health digital medicine program is caring for patients beyond its walls. In 2022, Ochsner Health treated more than 1.4 million people from every state and 62 countries. As Louisiana’s top healthcare educator of physicians, Ochsner Health and its partners educate thousands of healthcare professionals annually. To learn more, visit https://www.ochsner.org/.

    [ad_2]

    Ochsner Health

    Source link

  • Engineering of plant cell wall modifying enzymes opens new horizons

    Engineering of plant cell wall modifying enzymes opens new horizons

    [ad_1]

    Newswise — A newly discovered way of optimising plant enzymes through bioengineering has increased knowledge of how plant material can be converted into biofuels, biochemicals and other high-value products.

    The University of Adelaide-led study presents innovative ideas for how the walls of plant cells can be assembled, structured and remodelled by controlling specific enzymes’ catalytic function.

    Fundamental plant cell properties – such as structure, integrity, cytoskeletal organisation and stability – are now viewed differently, suggesting new alternatives.

    Studying the catalytic function of specific enzymes – a process termed ‘xyloglucan xyloglucosyl transferases’ – allowed researchers to better understand how they link diverse polysaccharides to form structural components of plant cell walls.

    “This work contributes to the essential knowledge of how xyloglucan xyloglucosyl transferases can be understood and their fundamental properties controlled – for example, to improve their catalytic rates and stability,” said project leader Professor Maria Hrmova.

    For plant material to be used in the production of biofuels, plant cell walls need to be deconstructed and the resultant materials chemically processed. The properties of the cell walls can be altered to be less rigid, therefore making biofuel production more efficient and cost-effective.

    The finding also has applications for the pharmaceutical industry, where enzymes are sought as environmentally friendly and cost-effective options in bioremediation, and other applications.

    Bioremediation is the removal of contaminants, pollutants and toxins from the environment through the use of living organisms.

    “Although the definition of the catalytic function of xyloglucan xyloglucosyl transferases has significantly progressed during the past 15 years, there are limitations, and still a lack of information, in how this knowledge can be organically implemented in the functionality of plant cell walls,” she said.

    This teamwork builds upon 60 years of xyloglucan chemical and biochemical research of this and other research groups.

    The research team used sensitive high-performance liquid chromatography with fluorescent reagents to monitor complex biochemical reactions of polysaccharides in an efficient way.

    “We also applied 3D molecular modelling and molecular dynamics simulations to gain insights into the mode of action of these enzymes on fast time scales,” Professor Hrmova said.

    “Our findings are supported by plant and cellular biology approaches we used to offer novel ideas on the function of these enzymes in vivo.”

    The study was published in the prestigious Plant Journal and was conducted with an international, multidisciplinary team of researchers from the Institute of Chemistry of the Slovak Academy of Sciences and the Huaiyin Normal University in China.

    It also received funding support from the VEGA Scientific Grant Agency and the Australian Research Council.

    A visualisation of reactant movements in a plant xyloglucan transferase enzyme can be seen here.

    [ad_2]

    University of Adelaide

    Source link

  • Digging deeper into how vaccines work against parasitic disease

    Digging deeper into how vaccines work against parasitic disease

    [ad_1]

    Newswise — COLUMBUS, Ohio – Scientists have established the effectiveness of vaccines they developed to prevent the disfiguring skin disease leishmaniasis in animal studies, and Phase 1 human trial planning is in motion for the most promising candidate. 

    But in new work, the research team has determined how these vaccine candidates, created using mutated disease-causing parasites, prompt molecular-level changes in host cells that have specific roles in helping generate the immune response. 

    Despite using the same CRISPR gene-editing technique to make the vaccines, the two species of Leishmania parasites on which the vaccines are based produced very different effects in the immunized host: One enables the immune response to unfold by inhibiting a host metabolite that suppresses immune activity, and the other drives up activation of a chemical pathway in a way that primes immune cells to fight pathogens. 

    “I think it’s an important finding in the sense that we show that in the big picture, yes, these vaccines are protective, but at the molecular level the mechanisms can be totally distinct,” said Abhay Satoskar, professor of pathology in The Ohio State University College of Medicine and co-leader of the research team. 

    “This is not only conceptually important, but if you can find how these things are modulating the immune response in the right direction, and identify the pathways, then perhaps those pathways could be used for developing new interventions,” said Satoskar, a senior author of two new papers describing the findings. 

    The primary vaccine was made by editing the genome of Leishmania major, which causes cutaneous leishmaniasis in tropical and subtropical regions of the Eastern Hemisphere, and a backup vaccine was made using Leishmania mexicana, a more virulent species found in South, Central and North America. 

    The study findings on the metabolic effects of the L. major and L. mexicana vaccines were published Aug. 29, 2023, in the journal iScience

    Leishmaniasis is prevalent in 90 countries affecting about 12 million people globally at any given time, but no licensed human vaccine yet exists and the only drug treatment for the skin lesions requires weeks of daily injections with unpleasant side effects. The more lethal visceral leishmaniasis affects organs and is fatal if left untreated. 

    In developing these live attenuated vaccines, Satoskar and colleagues applied new technology to the century-old Middle Eastern practice of leishmanization – introducing the live parasite to the skin to create a small infection that, once healed, leads to life-long immunity against further disease. 

    The researchers previously reported using CRISPR to delete centrin, the gene for a protein that supports the parasite’s physical structure, from the genomes of both L. major and L. mexicana. Experiments showed vaccinated mice remained clear of skin lesions and the number of parasites at the infection site were held at bay. 

    Digging deeper into the vaccines’ effects in these new studies, researchers inoculated mouse ears with a normal parasite, a mutated parasite vaccine or a placebo, mimicking the bite of a sand fly – in humans and animals, leishmania is transmitted through the bite of infected sand flies. 

    The team used mass spectrometry at the inoculation site to identify the most prominent metabolites – the amino acids, vitamins and other small molecules produced as a result of metabolism, the many chemical reactions that keep the body functioning. 

    Results showed the L. major vaccine promoted a pro-inflammatory metabolic response in mice by using the amino acid tryptophan to block signals from a molecule that helps suppress immunity. The L. mexicana vaccine, on the other hand, enriched a series of metabolic reactions that activated the necessary pro-inflammatory work of front-line immune cells.  

    “We took an unbiased approach to analyze the metabolites detectable at the inoculation site. There is growing interest in understanding the role immune cell metabolism plays in modulating immune function,” said Satoskar, also a professor of microbiology at Ohio State. “We also learned that by removing the centrin gene, we got rid of the parasites’ ability to manipulate metabolic pathways in a way that would impair development of protective immunity and, in fact, promoted vaccine-induced immunity. That’s important to know for a live attenuated vaccine – there is a unique case for each parasite species.” 

    Though this information is not required for regulatory approval of these vaccines, the data could prove useful to supplementing vaccination. 

    “There are only four existing drugs for leishmaniasis,” Satoskar said. “We need to know the mechanism of vaccines so the knowledge can be used to develop newer vaccines or newer drugs that target these pathways. What you learn from immunomodulation can be used for developing other therapeutic agents.”

    This research was funded by the Global Health Innovative Technology Fund and the Center for Biologics Evaluation and Research within the Food and Drug Administration (FDA). The FDA is a co-owner of two U.S. patents associated with the mutated Leishmania species. 

    Co-authors of both papers include Sreenivas Gannavaram and Hira Nakhasi, who co-led the L. major study, and Nazli Azodi and Hannah Markle, all of the FDA; Greta Volpedo of Ohio State; Timur Oljuskin of the USDA Animal Parasitic Diseases Laboratory; Shinjiro Hamano of Nagasaki University; and Greg Matlashewski of McGill University. Thalia Pacheco-Fernandez of Ohio State co-authored the L. mexicana paper and Parna Bhattacharya of FDA co-authored the L. major paper.

     

    #

     

    [ad_2]

    Ohio State University

    Source link

  • Myocardial infarction, the number one cause of sudden death, may be treated by modulating the immune response

    Myocardial infarction, the number one cause of sudden death, may be treated by modulating the immune response

    [ad_1]

    Newswise — Myocardial infarction, the number one cause of sudden death in adults and the number two cause of death in Korea, is a deadly disease with an initial mortality rate of 30%, and about 5-10% of patients die even if they are transported to a medical center for treatment. The number of myocardial infarction patients in Korea has been increasing steeply, from 99,647 in 2017 to 126,342 in 2021, an increase of 26.8% in five years. Until now, drug administration, percutaneous angioplasty, and arterial bypass surgery have been known as treatments, but they are difficult to apply to severe cases that do not respond to them.

    Dr. Yoon Ki Joung and Dr. Juro Lee of the Biomaterials Research Center at the Korea Institute of Science and Technology (KIST), together with Prof. Hun-Jun Park and Dr. Bong-Woo Park of the Catholic University of Korea College of Medicine, have developed a new treatment for myocardial infarction that uses nanovesicles derived from fibroblasts with induced apoptosis to modulate the immune response.

    Myocardial infarction is an ischemic heart disease in which the coronary arteries, the blood vessels that supply blood to the heart, become narrowed or blocked, resulting in insufficient blood supply to the heart muscle, which causes nutrient and oxygen deficiency in the myocardium, leading to poor heart function. According to market research firm Technavio, the global myocardial infarction therapeutics market is expected to reach $2.02 billion by 2026, at a CAGR of 4.7%. In recent years, stem cell-derived nanovesicles, such as exosomes, have been used to treat myocardial infarction by modulating the inflammatory response, but stem cells are difficult to produce in large quantities, limiting their economic viability.

    The research team identified the possibility of treating severe myocardial infarction by reducing the inflammatory response in the heart muscle through a nanomedicine based on apoptotic cells, which are cells that commit suicide due to biochemical changes in their cells. This response was achieved by attaching peptides specific to the site of ischemic myocardial infarction and substances specific to macrophage phagocytosis to the surface of fibroblasts. To this end, the team developed anti-inflammatory nanovesicles that can be delivered specifically to macrophages at the site of myocardial infarction.

    In animal studies, we found that intravenously injected nanovesicles were effectively delivered to the myocardial infarction site in rats and were specifically recruited to macrophages. As a result, the left ventricular ejection fraction, an indicator of the contractile force of the left ventricle, increased by more than 1.5 times compared to the control group for 4 weeks. In addition, the effects of reducing inflammation and fibrosis, and increasing blood vessels preservation rate enhanced cardiomyocytes survival, which resulted in cardiac function improvement.

    “This is the first study to use nanovesicles produced from apoptosis-induced cells to treat myocardial infarction, and it has the advantage of being able to mass-produce them because it uses other cells rather than stem cells,” said Dr. Yoon Ki Joung of KIST. “In the future, we plan to conduct a research to verify the effectiveness and safety of the treatment, including clinical trials, through a collaborative research with Catholic University of Korea Medical School and bio companies.”

     

    ###

    KIST was established in 1966 as the first government-funded research institute in Korea. KIST now strives to solve national and social challenges and secure growth engines through leading and innovative research. For more information, please visit KIST’s website at https://eng.kist.re.kr/

    This research was supported by the Ministry of Science and ICT (Minister Lee Jong-ho) through the Korea Research Foundation Nano and Material Technology Development Project and the Sejong Science Fellowship Program, and the results were published in the June issue of Advanced Functional Materials (IF:19.0, JCR top 4.7%), an international journal in the field of materials.

    [ad_2]

    National Research Council of Science and Technology

    Source link

  • New tool aligns data from tissue slices virtually

    New tool aligns data from tissue slices virtually

    [ad_1]

    Newswise — SAN FRANCISCO, CA—Imagine a few roughly cut slices of bread on a plate. With just those slices, could you picture, in fine detail, the loaf they came from?

    Now, imagine several thin slices of tissue from, say, a small tumor. You’ve tested which of several genes are active at every point across each slice’s length and width. With that two-dimensional data from just a few slices, could you predict which of the genes are active throughout the entire three-dimensional structure of the tumor? Not easy, right?

    Discerning the 3D makeup of a tumor—or other tissue—using data from just a few slices is a serious computational challenge. But a new method developed at Gladstone Institutes enables researchers to do just that. This approach, published in the journal Nature Methods, could allow for much deeper understanding of biological tissue samples.

    “Without that third dimension, you can miss a lot of what’s happening in tissue,” says Gladstone Senior Investigator Barbara Engelhardt, PhD, senior author of the study. “Putting together slices in 3D space should help us begin to answer questions for which 2D data falls short. For instance, what are the precise boundaries of a tumor? Where have immune cells infiltrated the tumor? Where in the tumor would be best to inject a treatment?”

    The new method, named Gaussian Process Spatial Alignment (GPSA), is not just for tumors. It can be applied to nearly any kind of tissue and any type of data obtained from tissue slices, such as the structure of cells or which genes or proteins are switched on within them—with broad implications for research and medicine.

    Filling in the Blanks

    One of the most widely used ways to understand biological tissue—whether from a patient with an illness or an animal in a lab—is to surgically remove some of the affected tissue and analyze it. In labs around the world, technicians may slice the removed tissue into thin pieces to view under a microscope or to test for the presence of specific molecules that could aid diagnosis, guide treatment, or hint at how well a drug is working.

    However, the time, budget, and computational power needed to analyze each slice means that researchers and doctors are often limited to just a few slices from different parts of the tissue. What’s more, tissue slices become physically warped when they are cut, processed, and analyzed in a lab, making it difficult to discern exactly how the slices line up and fit together within the overall 3D structure of the original tissue.

    “The first step in going from 2D slice data to a full, 3D picture of the tissue is to computationally reverse warping so that we can realign the slices in virtual space,” says Engelhardt, who is also a professor in the Department of Biomedical Data Science at Stanford University.

    To address this challenge, the GPSA method uses what Engelhardt and her team refer to as a two-layer Gaussian process. This statistical approach harnesses data from the 2D tissue slices and, in the first layer, fits the warped 2D slice onto a 3D model of the tissue. In the second layer, GPSA attributes to each point in the 3D model some data collected from the slice, such as what genes are turned on at that point. In this way, GPSA reverses warping virtually and enables a highly precise alignment of the slices.

    During this process, the GPSA model fills in the spaces between slices with predictions of gene or protein expression for every point throughout the tissue, ultimately generating a 3D “atlas” of the tissue.

    “Say you have four slices from different locations in a person’s breast cancer tumor, and for every point on each slice you know which of 20,000 genes are turned on or off,” Engelhardt says. “GPSA creates a fully query-able 3D atlas where, for any single ‘x, y, z’ coordinate, for any of the 20,000 genes, we can dive in and ask: What genes are on and off at this position in the tumor? And how certain are we in this estimate?”

    A Highly Flexible Framework

    With GPSA, researchers can construct tissue atlases with data obtained from slices of inconsistent sizes, using different technologies, and at different scales and levels of resolution. While prior methods require the 3D scaffolds or “coordinate frameworks” to be pre-specified, GPSA estimates this 3D framework from the 2D slices alone when a coordinate framework for the tissue does not yet exist. The new method can also combine multiple types of tissue-slice data—say, both information about which genes are switched on and information about cellular structure—into a single atlas.

    In addition, when applied to slices taken from the same tissue at different points in time, GPSA can generate atlases that predict how every location within the tissue changes over time. In this way, the technique could help deepen understanding of aging, how illnesses progress, or how different tissues develop in a growing organism.

    “Flexibility is one of the main strengths of our new tool,” Engelhardt says.

    She and her team are now conducting analyses to further demonstrate that flexibility. For instance, they have developed a method that could be used by labs on a budget to determine the minimum number of tissue slices needed—and the precise locations where those slices should be cut—for GPSA to construct a tissue atlas with the desired information.

    “The goal is to maximize the insights we can gain from tissue slices, in order to allow researchers and clinicians to deeply query 3D tissues that are well-studied or tumors that are unique to a patient, and ultimately improve healthcare,” Engelhardt says.

    ###

    [ad_2]

    Gladstone Institutes

    Source link

  • Tecnologia Inovadora Trata Cânceres De Cabeça E PescoçO

    Tecnologia Inovadora Trata Cânceres De Cabeça E PescoçO

    [ad_1]

    Newswise — JACKSONVILLE, Flórida — No mundo todo, o papilomavírus humano (HPV) é responsável por grande parte dos cânceres de cabeça e pescoço, de acordo com a Organização Mundial da Saúde. Nos Estados Unidos, o HPV está associado a cerca de 70 por cento dos cânceres de garganta e boca. E mais de 70 por cento desses cânceres são diagnosticados em homens, de acordo com os Centros de Controle e Prevenção de Doenças (Centers for Disease Control and Prevention, CDC) dos EUA.

    O tratamento dos cânceres de garganta e boca, também chamados de cânceres orofaríngeos ou cânceres de cabeça e pescoço, depende da localização e do estágio da doença, além de outros fatores.

    Dr. Phillip Pirgousis, cirurgião de cabeça e pescoço da Mayo Clinic na Flórida, diz que atualmente os pacientes contam com tratamentos cirúrgicos mais seguros e menos invasivos para cânceres de cabeça e pescoço, disponíveis graças a uma tecnologia inovadora.

    Casos de câncer relacionados ao HPV estão aumentando em duas áreas específicas da garganta.

    “Nas amígdalas na parte posterior da garganta e no tecido do linfonodo na parte posterior da língua”, relata o Dr. Pirgousis.

    Cânceres nesses dois locais podem ser um desafio.

    “Muitos dos desafios costumam estar relacionados à localização do tumor primário, porque é difícil acessar a garganta e a área da laringe ou caixa de voz”, explica ele.

    Diante desse cenário desafiador é que a inovação com robótica possibilita melhor visualização do tumor, melhor iluminação e melhores resultados em termos de completa remoção do tumor.

    “Estamos falando aqui de grandes cirurgias abertas comparadas com cirurgias minimamente invasivas, nas quais conseguimos acessar esses locais difíceis fazendo incisões faciais”, complementa ele.

    “E causando menor impacto na respiração, na fala, na deglutição e na comunicação. O robô cirúrgico melhorou nossa capacidade não só de remover completamente os tumores, mas de realizar essa remoção com segurança”, avalia o Dr. Pirgousis.

    Cirurgia robótica transoral

    cirurgia robótica transoral é uma técnica cirúrgica minimamente invasiva que usa um sistema de computador para ajudar a guiar as ferramentas cirúrgicas pela boca. Os braços robóticos são controlados por um cirurgião que opera um console e guia os braços para realizar a cirurgia. O console proporciona ao cirurgião uma visão 3D ampliada de alta definição do local da cirurgia. O cirurgião lidera outros integrantes da equipe que auxiliam durante a cirurgia.

    Opções de tratamento para cânceres de cabeça e pescoço

    tratamento é baseado em muitos fatores, incluindo localização, estágio do câncer, tipo de células envolvidas, a saúde geral e preferências pessoais dos pacientes. O paciente pode fazer receber apenas um tipo de tratamento, ou pode se submeter a uma combinação de tratamentos contra o câncer. A equipe médica trabalhará com o paciente para determinar o melhor plano de tratamento para o caso.

    O tratamento pode incluir:

    • Radioterapia
    • Cirurgia para remover o câncer que não se espalhou para outras áreas
    • Cirurgia para remover parte da garganta, caixa vocal ou nódulos linfáticos
    • Quimioterapia
    • Terapia medicamentosa
    • Imunoterapia

    ###

    Sobre a Mayo Clinic
    Mayo Clinic é uma organização sem fins lucrativos comprometida com a inovação na prática clínica, educação e pesquisa, fornecendo compaixão, conhecimento e respostas para todos que precisam de cura. Visite a Rede de Notícias da Mayo Clinic para obter outras notícias da Mayo Clinic.

    [ad_2]

    Mayo Clinic

    Source link

  • Mind what you eat and drink. Food and Water Safety stories for media.

    Mind what you eat and drink. Food and Water Safety stories for media.

    [ad_1]

    Food and drinking water quality are essential to our health. Below are some of the latest headlines from the Food and Water Safety channel on Newswise. 

    Cleaning water with ‘smart rust’ and magnets (Embargoed until 16-Aug-2023 5:00 AM EDT)

    -American Chemical Society (ACS)

    Current estimates of Lake Erie algae toxicity may miss the mark

    -Ohio State University

    New study identifies disparities in testing and treating well water among low-income, BIPOC households in NC

    -University of North Carolina at Chapel Hill

    Three out of every ten meals ordered from the main food delivery app in Brazil come from dark kitchens

    -Sao Paulo Research Foundation (FAPESP)

    UIC leads field study on home, water safety after Ohio chemical spill

    -University of Illinois Chicago

    NUS scientists develop a new class of artificial water channels for more efficient industrial water purification

    -National University of Singapore (NUS)

    In the wake of aspartame news, should you kick your diet soda habit? FSU experts weigh in

    -Florida State University

    School Meals Would Be Even Healthier if Compliant with U.S. Nutrition Standards, Study Finds

    -Tufts University

    New optimization strategy boosts water quality, decreases diversion costs

    -Chinese Academy of Sciences

    Be wary of low-acidity vinegar options when preserving food at home, Virginia Tech food safety experts say

    -Virginia Tech

    Eliminating public health scourge can also benefit agriculture

    -University of Notre Dame

    [ad_2]

    Newswise

    Source link

  • Tunable “Affibodies” Offer a New Approach to Healing Bone Fractures

    Tunable “Affibodies” Offer a New Approach to Healing Bone Fractures

    [ad_1]

    Newswise — Instead of bulky metal plates and screws, bone fractures might someday be healed via targeted, controlled delivery of a specialized bone-growth protein.

    University of Oregon researchers have developed a system to get that protein to the site of injury and release it gradually over time. Their approach uses small proteins called affibodies, which can be specially engineered to grab onto specific other proteins and release them at different rates.

    The team reports their results in a paper published June 28, 2023 in Advanced Healthcare Materials.

    Healing is a complex biological process, with many different proteins at the site of injury aiding in regeneration. “This initial proof of concept shows we can release things at different rates, like other proteins, to mimic how the bone would naturally regenerate,” said Jonathan Dorogin, a graduate student in Marian Hettiaratchi’s lab who led the design. Hettiaratchi is an assistant professor in the UO’s Phil and Penny Knight Campus for Accelerating Scientific Impact.

    One of these many healing-related proteins is bone morphogenetic protein-2, or BMP-2. Early in development, it helps bones form. And when someone breaks a bone, cells around the site of the fracture secrete this protein to help new bone grow. Recently, scientists and doctors have been interested in giving patients infusions of BMP-2 as a treatment to hasten healing.

    But BMP-2 is so powerful that it can easily lead to off-target effects, causing bone growth where it’s not wanted and leading to unexpected complications.

    Hettiaratchi and her colleagues have been trying to develop a more controlled strategy. Affibodies piqued the lab’s interest as a possible solution because they’re small and relatively simple to engineer, Hettiaratchi said. These molecules are cousins to antibodies, immune system molecules that selectively latch onto bacteria or viruses. But affibodies’ pared-down size makes them easier to generate in the lab. And because they’re engineered to be highly specific to the proteins they’re sticking to, there’s less risk of them interacting with other things they’re not supposed to in the body.

    The team screened a set of affibodies by testing how well they stuck to BMP-2, looking for molecules that would stick solidly but still release the protein under the right conditions. As candidate for further testing, they picked one affibody that stuck to BMP-2 more strongly, and another that had a weaker connection.

    They linked those affibodies with a squishy material called a hydrogel, which is often used as a delivery vehicle in the body for BMP-2 and similar treatments. Then, they tested how the whole package behaved in a liquid solution that mimics the environment inside the body.

    Adding affibodies to the hydrogel made it release BMP-2 more slowly than an affibody-free hydrogel, the researchers found. And changing up the affibodies could alter the rate of release, too.

     “Our innovation has been to control when the protein comes out,” Dorogin said.  

    In collaboration with colleagues in the lab of Knight Campus researcher Parisa Hosseinzadeh, the team also used machine learning to better understand how the affibodies were interacting with BMP-2.

    Hettiaratchi and Dorogin anticipate the work will be most useful for severe or complex fractures, where there’s a higher likelihood of a bone not healing correctly. They’ve filed a patent for the design of this BMP-2 delivery strategy, and are moving on to further testing with the hopes that someday, this tunable approach could be used in human patients. 

    They see affibodies as far more than just a platform for BMP-2 delivery, though. Healing is complicated, and the natural process involves a cascade of different molecules rushing to the site of injury at different times and in different quantities.

    Hettiaratchi ultimately envisions an affibody-based system that could deliver many healing-related proteins to the site of an injury, each one tuned to come in at a specific rate depending on when it’s needed during the healing process.

    “BMP-2 was a great protein to start with, because we knew it would be clinically relevant,” Hettiaratchi said. “But the long-term goal is to apply this to many things in the clinic.”

     – By Laurel Hamers, University Communications

    This research is funded in part by the Department of Defense and the National Institutes of Health. The team also received a pilot grant from the Collins Medical Trust.

    About the Knight Campus 
    The Phil and Penny Knight Campus for Accelerating Scientific Impact is a hub of discovery and innovation where teams of world-class bioengineers and bioscientists are driving groundbreaking scientific research and providing an innovative approach to technical training, professional development, and entrepreneurship. Made possible by a $500 million lead gift from Penny and Phil Knight in 2016 and a second $500 million gift in 2021, the Knight Campus is home to several research centers of excellence and offers a Ph.D. in bioengineering, a bioengineering minor and an accelerated master’s degree program with multiple industry focused tracks. 

    [ad_2]

    University of Oregon

    Source link

  • Structure of Opioid Receptors May Reveal How to Better Design Pain Relievers, Addiction Therapies

    Structure of Opioid Receptors May Reveal How to Better Design Pain Relievers, Addiction Therapies

    [ad_1]

    Newswise — Opioids remain the most potent and effective pain relievers in medicine, but they’re also among the most addictive drugs that can halt a person’s ability to breathe during an overdose — which can be deadly. Researchers have been racing to develop safer pain reliever drugs that target a specific opioid receptor, called the kappa opioid receptor, that is only found in the central nervous system and not elsewhere in the body, like other opioid receptors. Previous research suggests that such drugs may not lead to addiction or death due to overdose, but the currently known drugs that target these kappa opioid receptors have their own set of unacceptable side effects, including depression and psychosis.

    In one of the first steps towards eventually developing a new wave of kappa opioid receptor drugs without these side effects, researchers at the University of Maryland School of Medicine and Washington University have mapped the 3D structure of the central nervous system specific kappa opioid receptor and figured out how it differs from the other opioid receptors. In this new study, they discovered what instructs the kappa opioid receptor to change its shape, which uniquely binds to opioid drugs, akin to a lock fitting with a specific key.  

    They published their results in the May issue of Nature.

    Aside from relieving pain, opioid receptors are also involved in everything from sensing taste and smell to digestion and breathing, as well as responding to many of the body’s hormones. The way that opioid receptors can influence so many functions around the body is by acting with one of seven cell activity proteins, known as G-alpha proteins, that each help to specialize the function they suppress in the cell.

    “Knowing how these drugs interact with opioid receptors and having a clear view of this molecular snapshot is critical for allowing researchers to develop more effective pain-relieving drugs. This requires a drug that binds to the right type of opioid receptor, such as one in the central nervous system to reduce pain versus the ones that interact in the gut, causing side effects like constipation,” said study corresponding author Jonathan Fay, PhD, Assistant Professor of Biochemistry and Molecular Biology at UMSOM. “Additionally, these next generation medications will need to be designed with the appropriate kind of G-alpha protein in mind, as this will help to precisely target location and cell function by determining the specific shape of the opioid receptor — so the drug only reduces pain without affecting other body functions.”

    The known kappa opioid receptor drugs do not produce the same euphoria as traditional opioid drugs, making these kappa opioid receptor drugs less likely to be addictive.

    For the current study, the researchers used cryogenic electron microscopy in order to visualize the structure of the kappa opioid receptor. They first needed to flash freeze the receptors, which were bound to a hallucinogenic drug with one of two of the traditional G-alpha proteins. They then used a different drug to see how the kappa opioid receptor interacted with two other types of G-alpha proteins; one of these G-alpha proteins is found only in the central nervous system and the other is used to detect taste and smell.

    Dr. Fay described the G-protein as shaped like a chainsaw with a handle and a ripcord. Each G-protein had a slightly different position of its chainsaw handle when bound to the kappa opioid receptor. This change in position played an active role in determining the shape of the kappa opioid receptor and thus what drug bound the best to it. These findings ultimately could have implications for how new drugs will be designed.

    UMSOM Dean Mark T. Gladwin, MD, Vice President for Medical Affairs, University of Maryland, Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor, said, “Researchers face an enormous challenge in developing safer pain-reliever drugs since they will need to target both the correct opioid receptor as well as the appropriate G-alpha protein. Studies like these reinforce the mission of our new Kahlert Institute for Addiction Medicine, which aims to help develop this next generation of engineered small molecule drugs that are less addictive.

    The research was supported by National Institutes of Health grants from the National Institute of General Medical Sciences (R35GM143061) and the National Institute of Neurological Disorders and Stroke (R01NS099341). The Titan X Pascal graphics card used for this research was donated by NVIDIA.

    About the University of Maryland School of Medicine

    Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world — with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.3 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

    [ad_2]

    University of Maryland School of Medicine

    Source link

  • Fly Toolkit Created for Investigating COVID-19 Infection Mechanisms

    Fly Toolkit Created for Investigating COVID-19 Infection Mechanisms

    [ad_1]

    Newswise — Millions of deaths and ongoing illnesses caused by the COVID-19 pandemic have prompted scientists to seek new ways of understanding how viruses so skillfully enter and reprogram human cells. Urgent innovations leading to the development of new therapies are needed since virologists predict that future deadly viruses and pandemics may again emerge from the coronavirus family.

    One approach to developing new treatments for such coronaviruses, including the SARS-CoV-2 virus that causes COVID-19, is to block the mechanisms by which the virus reprograms our cells and forces them to produce more viral particles. But studies have identified nearly 1,000 human proteins that have the potential to bind with viral proteins, creating overwhelming challenges in identifying which of the many possible interactions are most relevant to infection.

    A multi-institutional collaboration has now developed a toolkit in fruit flies (Drosophila) to sort through the pile of possibilities. The new Drosophila COVID Resource (DCR) provides a shortcut for assessing key SARS-CoV-2 genes and understanding how they interact with candidate human proteins.

    The study, published in Cell Reports, was led by Annabel Guichard and Ethan Bier of the University of California San Diego and Shenzhao Lu, Oguz Kanca, Shinya Yamamoto and Hugo Bellen of the Baylor College of Medicine and Texas Children’s Hospital.

    “A defining feature of viruses is their ability to rapidly evolve—a characteristic that has proven particularly challenging in controlling the SARS-CoV-2 virus,” said Bier a professor in the UC San Diego School of Biological Sciences. “We envision that this new resource will offer researchers the ability to quickly assess the functional effects of factors produced by this once-in-a century pathogen as well as future naturally occurring variants.”

    The researchers designed the DCR as a versatile discovery system. It features an array of fruit fly lines that produce each of the 29 known SARS-CoV-2 proteins and more than 230 of their key human targets. The resource also offers more than 300 fly strains for analyzing the function of counterparts to human viral targets.

    “By harnessing the powerful genetic tools available in the fruit fly model system, we have created a large collection of reagents that will be freely available to all researchers,” Bellen said. “We hope these tools will aid in the systematic global analysis of in vivo interactions between the SARS-CoV-2 virus and human cells at the molecular, tissue and organ level and help in the development of new therapeutic strategies to meet current and future health challenges that may arise from the SARS-CoV-2 virus and related family members.”

    As they tested and analyzed the potential of the DCR, the researchers found that nine out of 10 SARS-CoV-2 proteins known as non-structural proteins (NSPs) they expressed in flies resulted in wing defects in adult flies. These defects can serve as a basis to understand how the viral proteins affect host proteins to disrupt or reorient essential cellular processes to benefit the virus.

    They also made an intriguing observation: one of these viral proteins, known as NSP8, functions as a type of hub, coordinating with other NSPs in a mutually reinforcing manner. NSP8 also strongly interacted with five of the 24 human binding candidate proteins, the researchers noted. They discovered that the human protein that exhibited the strongest interactions with NSP8 was an enzyme known as arginyltransferase 1, or “ATE1.”

    “ATE1 adds the amino acid arginine to other proteins to alter their functions,” said Guichard. “One such target of ATE1 is actin, a key cytoskeletal protein that is present in all of our cells.” Guichard noted that the researchers found much higher levels of arginine-modified actin than normal in fly cells when NSP8 and ATE1 were produced together. “Intriguingly, abnormal ring-like structures coated with actin formed in these fly cells,” she said, “and these were reminiscent of similar structures observed in human cells infected with the SARS-CoV-2 virus.”

    However, when flies were given drugs that inhibit the activity of the human ATE1 enzyme, the effects of NSP8 were considerably reduced, offering a path to promising new therapeutics.

    Calling their method a “fly-to-bedside” resource, the researchers say these initial results are just the tip of the iceberg for drug screening. Eight of the other NSPs they tested also produced distinctive phenotypes, laying the groundwork for pinpointing other new drug candidates.

    “In several cases, identification of new candidate drugs targeting functionally important viral-human interactions might prove valuable in combination with existing anti-viral formulations such as Paxlovid,” said Bier. “These new discoveries may also provide clues to the causes of various long-COVID symptoms and strategies for future treatments.”

    The complete coauthor list includes: Annabel Guichard, Shenzhao Lu, Oguz Kanca, Daniel Bressan, Yan Huang, Mengqi Ma, Sara Sanz Juste, Jonathan Andrews, Kristy Jay, Marketta Sneider, Ruth Schwartz, Mei-Chu Huang, Danqing Bei, Hongling Pan, Liwen Ma, Wen-Wen Lin, Ankush Auradkar, Pranjali Bhagwat, Soo Park, Kenneth Wan, Takashi Ohsako, Toshiyuki Takano-Shimizu, Susan Celniker, Michael Wangler, Shinya Yamamoto, Hugo Bellen and Ethan Bier.

    Funding for the study was provided by the National Institutes of Health (grants R24OD022005-07S1, R24OD022005, R24OD031447, R24OD031447-02S1, R01GM117321, R01GM144608 and R01AI162911); the Kyoto Institute of Technology; the Tata Trusts in India to the Tata Institute for Genetics and Society at UC San Diego; Jan and Dan Duncan Neurological Research Institute at Texas Christian Hospital; and a CAPES fellowship (88887.659907/2021-00).

    Note: Bier has equity interests in Synbal Inc., a company that may potentially benefit from the research results, and also serves on the board of directors and scientific advisory board of Synbal.

    [ad_2]

    University of California San Diego

    Source link

  • Brain cell sensor captures dynamic connections

    Brain cell sensor captures dynamic connections

    [ad_1]

    Newswise — Osaka, Japan – When brain cells, or neurons, are putting out processes to connect with other neurons, how do they tell the difference between their own processes and those of other neurons? One important part of this puzzle involves a molecule called clustered protocadherin (Pcdh).

    In a recent publication in iScience, researchers from SANKEN (The Institute of Scientific and Industrial Research) and the Graduate School of Frontier Biosciences at Osaka University reported the development of a sensor to look at Pcdh interactions in live neurons, which brings us closer to understanding this mystery.

    In the brain, millions of neurons make trillions of connections with each other. To do so, each neuron puts out tiny processes that grow and travel until they find another cell’s processes to connect with. However, because each cell has so many processes all over the place, cells can accidentally make connections with themselves rather than with others. One way to avoid this involves Pcdh, which is expressed in different combinations on each neuron’s surface.

    One role of Pcdh is in cell adhesion; if two neuronal processes have exactly the same combination of Pcdh molecules, the molecules bind to one another. Conversely, if the combinations are even slightly different, they are viewed as “other” rather than “self,” and do not bind. Although there are conventional techniques for detecting molecular interactions between cell surfaces, which can show us when the molecules bind, but not when they split apart again. Researchers from Osaka University wanted to tackle this issue.

    “We developed a fluorescent-based sensor that we named IPAD, or Indicators for Protocadherin Alpha 4 interactions upon Dimerization,” says lead author of the study Takashi Kanadome. “This sensor allows us to see not only interactions between processes, but also the dissociation of these interactions for the first time.”

    This new technique does have a few disadvantages. For example, its fluorescence is much duller than that observed using older techniques, and it is unable to differentiate connections between processes from the same cell and those from two different cells with the same combinations of Pcdh on the surface. 

    “Despite its current drawbacks, we think that our new sensor will be useful for a number of different research applications,” explains Tomoki Matsuda, senior author of the study. “The development of IPAD is an important step toward a better understanding of the neuronal recognition of self/other.”

    The sensors developed in this study have many potential applications. In particular, the technique may be used to develop a range of fluorescent sensors to visualize neuronal self-connectivity, which is implicated in brain disorders such as autism and epilepsy. A better understanding of neuronal self-connectivity may lead to improved treatments for these disorders.

    ###

    The article, “Visualization of trans-interactions of a protocadherin-α between processes originating from single neurons,” was published in iScience at DOI: https://doi.org/10.1016/j.isci.2023.107238

    [ad_2]

    Osaka University

    Source link

  • This sugar kills honeybees—it could also help fight cancer

    This sugar kills honeybees—it could also help fight cancer

    [ad_1]

    Newswise — LA JOLLA, CALIF. – July 18, 2023 – Research from Sanford Burnham Prebys and the Osaka International Cancer Institute has shed new light on the anti-cancer properties of mannose, a sugar that is crucial to many physiological processes in humans and is also known to inhibit the growth of cancer cells. The findings, published in the journal eLife, suggest that mannose could be a helpful secondary treatment for cancer.

    “This sugar could give cancer an extra punch alongside other treatments,” says study co-author Hudson Freeze, Ph.D., director of the Human Genetics Program at Sanford Burnham Prebys. “And because mannose is found throughout the body naturally, it could improve cancer treatment without any undesirable side effects.”

    Mannose is a sugar that the body adds to proteins to stabilize their structure and help them interact with other molecules. This process, called glycosylation, is essential for life; and malfunctions in glycosylation are associated with rare, but often life-threatening, human diseases.

    “Until now, the most promising therapeutic use for mannose was to treat congenital disorders of glycosylation, diseases that can cause a wide range of severe symptoms throughout the body,” says Freeze. “But we believe that there may be ways to leverage mannose against cancer and other diseases as well.”

    Mannose has already been shown to inhibit the growth of several types of cancer in the lab, but scientists don’t fully understand why this happens. To learn more, the research team turned their attention to an unusual property of mannose observed in an unlikely subject: honeybees. 

    “It’s been known for more than a century that mannose is lethal to honeybees because they can’t process it like humans do—it’s known as ‘honeybee syndrome,’” says Freeze. “We wanted to see if there is any relationship between honeybee syndrome and the anti-cancer properties of mannose, which could lead to an entirely new approach to combat cancer.” 

    Using genetically engineered human cancer cells from fibrosarcoma—a rare cancer that affects connective tissue—the research team re-created honeybee syndrome and discovered that without the enzyme needed to metabolize mannose, cells replicate slowly and are significantly more vulnerable to chemotherapy. 

    “We found that triggering honeybee syndrome in these cancer cells made them unable to synthesize the building blocks of DNA and replicate normally,” says Freeze. “This helps explain the anti-cancer effects of mannose that have we’ve observed in the lab.” 

    While leveraging honeybee syndrome could be a promising supplemental cancer treatment, the researchers caution that because the effect is dependent on vital metabolic processes, more research is needed to determine which types of cancer would be most vulnerable to mannose.

    “If we can find cancers that have a low activity of the enzyme that processes mannose, treating them with mannose could give just enough of a nudge to make chemotherapy more effective,” says Freeze. “Many people assume that you always discover treatments in response to the disease, but sometimes you find biology that could be useful for treatment and then have to find the disease to match it.”

    In the meantime, the study speaks to the broader potential of glycosylating sugars for cancer treatment, which is still an emerging area of research. 

    “The glycobiology of sugar metabolism within cancer cells is still an unexplored frontier, and it could be an untapped treasure trove of potential treatments just waiting to be discovered,” adds Freeze. 

    ###

    Additional authors on the study include Yoichiro Harada, Yu Mizote, Toru Hiratsuka, Yusuke Imagawa, Kento Maeda, Yuki Ohkawa, Shigeki Higashiyama, Hideaki Tahara and Naoyuki Taniguchi, Osaka International Cancer Institute; Takehiro Suzuki and Naoshi Dohmae, RIKEN Center for Sustainable Resource Science; Akiyoshi Hirayama, Satsuki Ikeda and Junko Murai, Keio University; Mikako Nishida and Heiichiro Udono, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; and Ayaka Ueda and Eiji Miyoshi, Osaka University. 

    The study was supported by the Takeda Science Foundation, JSPS KAKENHI (JP23K06645), the Rocket Fund, and the National Institutes of Health (R01DK99551).

    The study’s DOI is 10.7554/eLife.83870.

    About Sanford Burnham Prebys

    Sanford Burnham Prebys is an independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 45 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children’s diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at SBPdiscovery.org or on Facebook facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.

    [ad_2]

    Sanford Burnham Prebys

    Source link

  • Trevor Charles appointed to the Phytobiomes Alliance Board of Directors

    Trevor Charles appointed to the Phytobiomes Alliance Board of Directors

    [ad_1]

    Newswise — The International Alliance for Phytobiomes Research is pleased to announce the appointment of Trevor Charles as a new Board member of the organization.

    Trevor Charles is Professor in the Department of Biology at University of Waterloo in Canada and Director of the Waterloo Centre for Microbial Research. A microbiologist with expertise in bacterial molecular genetics, Charles’ research focuses on plant-microbe interactions, functional metagenomics, and bacterial genome engineering for bio-products. Charles is Founder and CEO of the company Metagenom Bio Life Science Inc., a biotech company specializing in DNA sequencing solutions for microbiome research and analysis. He is also spearheading Healthy Hydroponics InnoTech Inc., a subsidiary of Metagenom Bio Life Science, a company providing pathogen monitoring services to hydroponic farms and growers to enhance prediction of crop diseases and food safety, as well as serving as CSO of the new inoculant company Earth Microbial Inc.

    “I am truly honored to join the board of Phytobiomes Alliance, an organization that I have held in high esteem for its forward-looking role in the translation of Phytobiomes science with the ultimate aim of producing food in a more environmentally and economically sustainable manner,” said Trevor Charles.  “I look forward to making contributions to the Phytobiomes Alliance and its varied stakeholders through membership on the Board. I am excited to collaborate with the other passionate Board members to drive positive change with the aim of creating a lasting impact on global food systems.”

    “We are extremely pleased to have Trevor join the Board, he has been a continuous supporter of the Alliance internationally and a pioneer in expanding our understanding of microbes as part of controlled environment agriculture phytobiomes as well as designing microbial solutions specifically for these environments. The sustainable production of food, feed, and fiber in controlled environments will be important for fulfilling our needs for fresh and locally produced food in the future,” said Kellye Eversole, the Alliance Executive Director. “Trevor’s leadership and vision will be invaluable to shaping the Alliance strategy for the coming years.”

    Charles has been a member of the Alliance Coordinating Committee since 2018. He was selected for the Board of Directors for his continuous efforts in supporting and promoting the overall advancement of phytobiomes science, and in particular for his leadership in controlled environment agriculture.

    Launched in 2016, the non-profit International Phytobiomes Alliance facilitates and coordinates international efforts toward expanding phytobiomes research in order to accelerate the sustainable production of food, feed, and fiber for food security. The Board of Directors is in charge of setting the overall vision and mission of the Alliance and provides general oversight for the Alliance operations.

    Charles will join the current Board members, Gwyn Beattie (Iowa State University), Natalie Breakfield (Newleaf Symbiotics), Kellye Eversole, Magalie Guilhabert (Ginkgo Bioworks), Jan Leach (Colorado State University), Emmanuelle Maguin (INRAE), Matthew Ryan (CABI) and Angela Sessitsch (Austrian Institute of Technology) for a three-year term.

    About the Phytobiomes Alliance

    The Phytobiomes Alliance is an international, nonprofit alliance of industry, academic, and governmental partners created in 2016. The goal of the Alliance is to understand, predict and control emergent phenotypes for sustainable production of food, feed and fiber on any given farm. The Phytobiomes Alliance is sponsored by Eversole Associates, INRAE, Valent BioSciences, Colorado State University, FarmBox Foods, IRD, Joyn Bio, the University of Nebraska-Lincoln, NewLeaf Symbiotics, Penn State College of Agricultural Sciences, Pivot Bio, Trace Genomics, the Waterloo Centre for Microbial Research, Aphea.Bio, and AIT Austrian Institute of Technology.

    To learn more about the Alliance, visit phytobiomesalliance.org and follow @phytobiomes on Twitter. 

    [ad_2]

    International Phytobiomes Alliance

    Source link

  • Killing Cancer in a Flash

    Killing Cancer in a Flash

    [ad_1]

    Newswise — BALTIMORE, July 8, 2023 – Radiation therapy is a common treatment used to kill cancerous cells. However, healthy cells also sustain damage during the lengthy treatment process. FLASH is a targeted radiation therapy that kills tumor cells while sparing healthy tissue. Like its namesake, FLASH delivers a short, intense burst of radiation in a single appointment. Despite this breakthrough’s proven ability, little is known about its mode of action against tumor cells.

    Corie Ralston, from Lawrence Berkeley National Laboratory, will present her team’s research using X-ray footprinting mass spectrometry to investigate the mechanisms that make FLASH a powerful cancer killer at the 73rd annual meeting of the American Crystallographic Association, which will be held July 7-11 at the Baltimore Marriott Waterfront Hotel. She will present her work Saturday, July 8, at 9:30 a.m. in room Laurel AB.

    “FLASH refers to the phenomenon that very high dose rate irradiation will spare healthy tissue around a tumor, but still kill tumor cells to the same degree as conventional dose rate radiation,” said Ralston. “The fact that this will spare healthy tissues is counterintuitive but has been demonstrated using different modes of radiation (X-ray, electron, proton) and in cells, tissues, and several animal models.”

    First discovered in 2014, FLASH treatment can be significantly more potent than conventional treatment. There are many possible explanations as to why this more intense therapy works at the cellular level. One possibility is that high dose radiation produces extremely reactive ions and molecules that selectively damage cancer cells. Alternatively, the immune system might respond differently to the dosage level.

    The research conducted by Ralston and her team points to a third theory – that a FLASH-induced low oxygen environment protects surrounding cells from further damage. At low oxygen levels, radiation induces fewer harmful modifications to proteins.

    Using X-ray footprinting mass spectrometry to map specific protein modifications in cells under varying irradiation dose rates, the team found that oxygen is consumed quickly during treatment.

    “We also found that high dose rate irradiation alters proteins less than low dose rate irradiation. This was counterintuitive, but matched the FLASH effect on healthy tissues,” Ralston said.

    Both results support the “oxygen depletion effect” and lay the groundwork for future research using the X-ray footprinting method. With more mechanistic insights gained into FLASH, tailored dosage rates and treatment plans could be developed for each cancer type or patient.

    “FLASH has generated huge interest in recent years and has been described as a breakthrough in radiation oncology,” said Ralston. “If the current clinical trials in humans hold up, then it might become the new standard of care for cancer treatment. It would mean that cancerous tumors could be treated faster and with far fewer side effects.”

    ###

    ———————– MORE MEETING INFORMATION ———————–

    IMPORTANT LINKS

    Main meeting website: https://www.acameeting.com/ 
    Technical program: https://www.acameeting.com/full-program

    PRESS REGISTRATION FOR MEETING SESSIONS

    We will grant free registration for credentialed and professional freelance journalists who wish to attend the meeting sessions. If you are a reporter and would like to attend, contact the AIP Media Line at [email protected]. We can also help with setting up interviews and obtaining images, sound clips or background information.

    ABOUT AMERICAN CRYSTALLOGRAPHIC ASSOCIATION

    The American Crystallographic Association, Inc. is a nonprofit, scientific organization of more than 1,000 members in more than 35 countries. The ACA was founded in 1949 through a merger of the American Society for X-Ray and Electron Diffraction (ASXRED) and the Crystallographic Society of America (CSA). The objective of the ACA is to promote interactions among scientists who study the structure of matter at atomic (or near atomic) resolution. These interactions will advance experimental and computational aspects of crystallography and diffraction. Understanding the nature of the forces that both control and result from the molecular and atomic arrangements in matter will help shed light on chemical interactions in nature.

    ##

    [ad_2]

    American Crystallographic Association (ACA)

    Source link

  • Long Covid not caused by COVID-19 immune inflammatory response, new research finds

    Long Covid not caused by COVID-19 immune inflammatory response, new research finds

    [ad_1]

    Newswise — Long Covid, which affects nearly two-million people in the UK1, is not caused by an immune inflammatory reaction to COVID-19, University of Bristol-led research finds.  Emerging data demonstrates that immune activation may persist for months after COVID-19.

    In this new study, published in eLife today [4 July], researchers wanted to find out whether persistent immune activation and ongoing inflammation response could be the underlying cause of long Covid.  

    To investigate this, the Bristol team collected and analysed immune responses in blood samples from 63 patients hospitalised with mild, moderate or severe COVID-19 at the start of the pandemic and before vaccines were available. The team then tested patients’ immune responses at three months and again at eight and 12 months post hospital admission. Of these patients, 79% (82%, 75%, and 86% of mild, moderate, and severe patients, respectively) reported at least one ongoing symptom with breathlessness and excessive fatigue being the most common.

    Dr Laura Rivino, Senior Lecturer in Bristol’s School of Cellular and Molecular Medicine and the study’s lead author, explained: “Long Covid occurs in one out of ten COVID-19 cases, but we still don’t understand what causes it.  Several theories proposed include whether it might be triggered by an inflammatory immune response towards the virus that is still persisting in our body, sending our immune system into overdrive or the reactivation of latent viruses such as human cytomegalovirus (CMV) and Epstein Barr virus (EBV).”

    The team found patients’ immune responses at three months with severe symptoms displayed significant dysfunction in their T-cell profiles indicating that inflammation may persist for months even after they have recovered from the virus. Reassuringly, results showed that even in severe cases inflammation in these patients resolved in time. At 12 months, both the immune profiles and inflammatory levels of patients with severe disease were similar to those of mild and moderate patients.

    Patients with severe COVID-19 were found to display a higher number of long Covid symptoms compared to mild and moderate patients. However, further analysis by the team revealed no direct association between long Covid symptoms and immune inflammatory responses, for the markers that were measured, in any of the patients after adjusting for age, sex and disease severity.

    Importantly, there was no rapid increase in immune cells targeting SARS-CoV-2 at three months, but T-cells targeting the persistent and dormant Cytomegalovirus (CMV) — a common virus that is usually harmless but can stay in your body for life once infected with it— did show an increase at low levels. This indicates that the prolonged T-cell activation observed at three months in severe patients may not be driven by SARS-CoV-2 but instead may be “bystander driven” i.e. driven by cytokines. 

    Dr Rivino added: “Our findings suggest that prolonged immune activation and long Covid may correlate independently with severe COVID-19. Larger studies should be conducted looking at both a larger number of patients, including if possible vaccinated and non-vaccinated COVID-19 patients, and measuring a larger range of markers and cytokines.  

    “Understanding whether inflammation and immune activation associate with long Covid would allow us to understand whether targeting these factors may be a useful therapy for this debilitating condition.”

    The study was supported by the Elizabeth Blackwell Institute (EBI) with funding from the University of Bristol’s alumni and friends and Southmead Hospital Charity.

    Paper

    ‘Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months’ by Marianna Santopaolo, Michaela Gregorova, Laura Rivino et al. in eLife [open access]

    [ad_2]

    University of Bristol

    Source link